Modis Therapeutics, Inc. Email Format

BiotechnologyCalifornia, United States51-200 Employees

Modis Therapeutics, Inc. operates within the biotechnology research sector as a subsidiary of Zogenix, Inc. Its focus is on developing disease-modifying therapies for rare genetic diseases with high unmet medical need, with MT1621 identified as its lead program for thymidine kinase 2 deficiency, an inherited mitochondrial disorder. Located in Emeryville, California, Modis Therapeutics is positioned to address complex mitochondrial and genetic disease challenges through clinical development, leveraging its affiliation with Zogenix to pursue targeted therapies for affected patients and their families. The company emphasizes ethical conduct and core values such as compassion, courage, collaboration, and excellence, and it collaborates within a broader family of rare-disease initiatives. A recent development notes Zogenix announced an acquisition of Modis Therapeutics in 2019, reflecting the integration of Modis into a larger pharmaceutical organization focused on rare diseases.

Get verified Modis Therapeutics, Inc. emails free

Company overview Employee directory